Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Ephraim Mcdowell Regional Medical Center Unveils Xenex Germ Killing Robot - Yahoo Finance

Cleanint Rolls Out Cleanstethoscope and Cleanhands to Largest Medical Transportation Company in the Nation - Yahoo Finance

AMR Cleanstethoscope This current donation to the medical center further demonstrates to those who charitably support the growth of health care services through the Foundation that critical needs are being funded. 100 percent of every donation goes to the funding of health care needs. Uniquely designed for ease of use and portability, the hospitals environmental services staff can operate the Xenex robot without disrupting hospital operations. With a five-minute disinfection cycle, the robot can disinfect dozens of hospital rooms per day, including patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. More than 250 hospitals, Veterans Affairs and DoD facilities in the U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ephraim-mcdowell-regional-medical-center-214300261.html

SNGX: Updated Preclinical Data on RiVax Presented - Yahoo Finance

The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world. For more information, visit Actavis' website at www.actavis.com .
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/actavis-receives-approval-european-commission-133000019.html

ViaDerma, Inc., to Initiate Upcoming Field Trial of Comparison for Onychomycosis - Yahoo Finance

For more information, please visit www.viadermalicensing.com . Forward Looking Statements This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/viaderma-inc-initiate-upcoming-field-141701919.html

DISC Sports & Spine Center Taps Dr. Dean K. Matsuda to Launch Hip Arthroscopy Center of Excellence

Dean K. Matsuda to Launch Hip Arthroscopy Center of Excellence Board certified orthopedic surgeon is an innovator in minimally invasive hip surgery with 26 years of sports medicine experience Dean K. Matsuda, MD: Director, Hip Arthroscopy at DISC With his compelling background of success stories in hip arthroscopy, Dr.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/03/prweb12550912.htm

Actavis Receives Approval from the European Commission for XYDALBA? (dalbavancin) - Yahoo Finance

Of those, MRSA (Methicillin-resistant Staphylococcus Aureus), a highly contagious disease, infects approximately 94,000 people resulting in about 19,000 deaths. Each of these and more, not listed, are diseases that are easily transmitted through casual contact with other infectious individuals, contact with surfaces that have been contaminated, or breathing contaminated air.Globally, infectious diseases account for 1 in 3 deaths. View photo . Today, Cleanint, an innovative developer of non-disposable cleaning and sanitizing devices is proud to announce that the more than 19,000 paramedics, emergency medical technicians (EMT), doctors, and nurses of American Medical Response (AMR), the largest private emergency medical provider in America, will be the first emergency medical service providers in the world to use Cleanint's new devices to combat the spread of infectious diseases.With items such as the Cleanstethoscope and Cleanhands , AMR will move to the forefront of fighting the transmission of infectious diseases when responding to medical services. "Cleanstethoscope is a http://mrsahelp.info/quick-mrsa-infections-natural-remedy-review-in-tunnelton/ game changer when you're dealing with an emergency or any other medical response as everyone from the basic EMT to the Physician uses a stethoscope multiple times during their shift on multiple people.The spread of infectious diseases from coming into contact with the unclean stethoscope alone is not only possible but probable," said Tuan Dam, CEO at Cleanint, "We looked at all the patient touch-points and the stethoscope stood out as a red flag. It's an opportunity to solve a very serious problem!" "With Cleanstethoscope, it is easier to disinfect your stethoscope after every use, further ensuring it is not contaminated," said Mike Taigman, general manager of AMR. "The healthcare industry has spent more than a century focused on building tools for clinicians so they can follow good infection control procedures.Cleanint builds good hygiene practices into the everyday systems of care, which makes it much easier for clinicians to do the right thing every time, all of the time." The Cleanhands will be worn by paramedics and EMTs ensuring that they will have instant access to an FDA approved hand disinfectant so they can further cut down the transmission of infectious diseases when moving from one patient to another in crisis situations or just a routine transport of a patient. AMR will be purchasing 50,000 AMR-branded Cleanstethoscope and Cleanhands units to be used by field personnel. Founded in 2009, Cleanint began with a singular concept: it's simple it's clean. This principle is at the heart of everything we develop.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/cleanint-rolls-cleanstethoscope-cleanhands-largest-140000295.html

The Animal Rule provides that under certain circumstances, where it is unethical or not feasible to conduct human efficacy studies, the FDA may grant marketing approval based on adequate and well-controlled animal studies when the results of those studies establish that the drug is reasonably likely to produce clinical benefit in humans. Demonstration of the product's safety in humans is still required. In addition to SGX943, Soligenix is also developing SGX101 for melioidosis. SGX101 is a monoclonal antibody (Mab) or monoclonal antibody cocktail developed by Soligenix with collaboration with Intrexon Corporation (XON) as a passive immunotherapy. Passive immunotherapy utilizes antibodies in the same manner a host-derived antibody would be used, targeting and labeling foreign entities and infected cells. SGX101 is intended as a human Mab therapy directed at host cells infected with Bp. SGX101 may also be utilized in conjunction with available antibiotic therapy. Either SGX943 or SGX101, if successful, may be extended to other difficult to treat bacterial infections. In particular, the IDR approach could be directly translated to other infections. In the case of SGX101, the product bacterial infection mrsa would be specific to Bp and perhaps Bm infection but the process whereby the product was identified could be generalized to other difficult to treat infections with intracellular bacteria. With these two distinctive anti-melioidosis programs, Soligenix is emerging as a key player in this specific field. There is still Room for Further Price Appreciation We maintain an Outperform rating for Soligenix and keep our 12-month price target of $5.50 per share. We believe there is still enough room for further price appreciation. Soligenix becomes a late development stage biotech company through the acquisition of SGX301, a Phase III candidate for CTLC. Soligenix is focused on cancer/cancer supportive care and GI disorders, two large pharmaceutical markets both in the US and around the world. Soligenix also develops vaccines/oral therapeutics for biodefense. In addition to SGX301, Soligenix has built a diversified pipeline using three proprietary platform technologies: the SGX942 platform, the oral BDP platform and the ThermoVax platform.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/sngx-updated-preclinical-data-rivax-172500607.html

Don't be the product, buy the product!